Inside This Special Issue: Neurotech 2009
Top News Alerts: Product Updates, Deals & Financings
Featured Topic: Highlights from Collaborating for Cures
Featured Company: Azevan
Subscribe now to access over 30 articles covering developments in drugs, devices and diagnostics for the brain and nervous system.
Market Highlights: Neurotech Venture Investing Down 22% in 2008, Revenues up 9%
It was a relatively upbeat month in neurotech with all but 5 companies in the NASDAQ NeuroInsights Neurotech Index (^NERV) posting gains. Vanda (VNDA) and Titan (XNPT), both previously on the brink of collapse, got new life after Fanapt received a surprise approval from the FDA for the treatment of schizophrenia (see story, page 3). The stocks were up a whopping 1,350% and 2,760%, respectively this month. Titan scrambled to rehire key executives and Vanda had the satisfaction of silencing Tang Capital which had been calling for its liquidation. The rough seas aren’t over yet, however. Neurogen (NRGN) put itself up for auction citing market factors and scarce funding for development stage public companies (see story, page 9). Catalyst reported a failed Phase III for the only drug in their pipeline, vigabatrin for cocaine addiction (see story, page 8)...
Neurotech 2009: Investors, Major Players & Emerging Companies Look to the Year Ahead
Investors, emerging companies and prospective commercialization partners convened in San Francisco at Neurotech 2009 to explore the state of the industry and the future of drugs, devices, and diagnostics for the brain and nervous system. Neurotechnology Industry Organization (NIO) founder Zack Lynch highlighted topline results and key trends to open the conference with findings from the annual Neurotech Industry Report published by NeuroInsights. Non-psychiatric neurological diseases affect over 1 billion people worldwide. Adding psychiatric conditions brings the worldwide total number of people affected to 2 billion with over 100 million in the US alone. Brain-related illnesses were responsible for $1.3 trillion in costs and lost income in the US in 2008...
Azevan: A Novel Platform for Vasopression Modulation in Stress Related Disorders
Azevan Pharmaceuticals is a private 10 person Bethlehem Pennsylvania company focused on drug discovery and development for disorders of stress, mood, and behavior. The company leverages a unique chemistry platform based on a beta-lactam scaffold to produce compounds that cross the blood brain barrier and target G-protein coupled receptors (GPCRs). Azevan's clinical candidates selectively block the effects of arginine vasopressin, which is involved in various mood-related conditions such as anxiety, depression, menstrual cycle disorders, and Raynaud's syndrome…
Companies Covered In This Issue Include: Second Sight, Acorda, Vanda, Titan, Acadia, Biovail, Targacept, Dara, Stem Cell Therapeutics, Neuroscience Inc., Cadence, St. Jude, Jannsen, AGI Therapeutics, Bio-Matrix, Avineuro, Neuronetics, NeurogesX, Tioga, Eli Lilly, Medtronic, UCB, Allergan, MAP Pharmaceuticals, Catalyst, Autonomic Technologies, Teikoku, Travanti, Endo, ChanTest, Orasi, Northstar Neuro, Neurogen, Tobii, Ovalis, Sciele, Victory, Satiety, Elixir, Avid Radiopharmaceuticals, Palyon, SetPoint Medical, Xanodyne, Sierra Pharmaceuticals, Alexza, PsychoGenics, MicroTransponder, Accera, NeuroNexus, Neurologix, Genzyme, Pfizer, Boston Scientific, Roche, StemCells Inc., Sound Pharmaceuticals, NeuroNova, Q Therapeutics, Impax, Merck, Addex, Bayhill therapeutics, Intellect Neurosciences, Nabi BioPharmaceuticals, Neurolutions, Xytis, Brainscope, NFocus, NeuroPace, EOS Neuroscience, Proteus BioMedical, Corcept, Targacept, Azevan, Brain Resource, SynSonix, Psychogenics and more
Subscribe Now:
|
|
